Radiation therapy firm Accuray has launched the Prostate Advances in Comparative Evidence (PACE) study.
The purpose of the international, randomized study is to compare Accuray's CyberKnife stereotactic body radiation therapy (SBRT) system, da Vinci-assisted and manual laparoscopic surgery, and intensity-modulated radiation therapy (IMRT) for treating localized prostate cancer.
The study is expected to include 30 to 40 medical centers and enroll more than 1,000 patients who will be followed for 10 years. Researchers plan to collect and report data outcomes at one, two, and five years after treatment.
The PACE Study was created by a consortium of academic centers in Europe, including Royal Marsden NHS Foundation Trust in the U.K., Center Oscar Lambret in France, Charite-Universitatsmedizin in Germany, Erasmus MC-Daniel den Hoed Cancer Center in the Netherlands, and Mount Vernon Cancer Centre in the U.K.
